Publicaties

1 - 10 of 10 resultaten

Sorteren op
Zoek term:

Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study KU Leuven

Klaus Pietzner, Ignace Vergote, Armando Santoro, Radoslav Chekerov, Frederik Marmé, Per Rosenberg, Holger Martinius, Hilke Friccius-Quecke, Jalid Sehouli
Malignant ascites is a common phenomenon in cancer patients. It poses a great challenge to the clinician, because of limited treatment options and strong impairment of the quality of life of the often palliative patients. The SECIMAS study investigated the feasibility of a re-challenge with four catumaxomab intraperitoneal infusions in patients who had already received a first cycle of four infusions in the phase III CASIMAS study, which ...

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure KU Leuven

SE DePrimo, X Huang, ME Blackstein, CR Garrett, CS Harmon, Patrick Schöffski, MH Shah, J Verweij, CM Baum, GD Demetri, et al.
Purpose: To evaluate changes in circulating levels of soluble KIT (sKIT) extracellular domain as a potential biomarker for clinical outcome in gastrointestinal stromal tumor patients treated with the multitargeted tyrosine kinase inhibitor sunitinib following imatinib failure in a previously reported phase III study. Experimental Design: Patients received sunitinib 50 mg/d (n = 243) or placebo (n = 118) daily in 6-week cycles (4 weeks on, 2 ...